Rediscovery of antimicrobial peptides as therapeutic agents. 2021

Minkyung Ryu, and Jaeyeong Park, and Ji-Hyun Yeom, and Minju Joo, and Kangseok Lee
Department of Life Science, Chung-Ang University, Seoul, 06974, Republic of Korea.

In recent years, the occurrence of antibiotic-resistant pathogens is increasing rapidly. There is growing concern as the development of antibiotics is slower than the increase in the resistance of pathogenic bacteria. Antimicrobial peptides (AMPs) are promising alternatives to antibiotics. Despite their name, which implies their antimicrobial activity, AMPs have recently been rediscovered as compounds having antifungal, antiviral, anticancer, antioxidant, and insecticidal effects. Moreover, many AMPs are relatively safe from toxic side effects and the generation of resistant microorganisms due to their target specificity and complexity of the mechanisms underlying their action. In this review, we summarize the history, classification, and mechanisms of action of AMPs, and provide descriptions of AMPs undergoing clinical trials. We also discuss the obstacles associated with the development of AMPs as therapeutic agents and recent strategies formulated to circumvent these obstacles.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D001419 Bacteria One of the three domains of life (the others being Eukarya and ARCHAEA), also called Eubacteria. They are unicellular prokaryotic microorganisms which generally possess rigid cell walls, multiply by cell division, and exhibit three principal forms: round or coccal, rodlike or bacillary, and spiral or spirochetal. Bacteria can be classified by their response to OXYGEN: aerobic, anaerobic, or facultatively anaerobic; by the mode by which they obtain their energy: chemotrophy (via chemical reaction) or PHOTOTROPHY (via light reaction); for chemotrophs by their source of chemical energy: CHEMOLITHOTROPHY (from inorganic compounds) or chemoorganotrophy (from organic compounds); and by their source for CARBON; NITROGEN; etc.; HETEROTROPHY (from organic sources) or AUTOTROPHY (from CARBON DIOXIDE). They can also be classified by whether or not they stain (based on the structure of their CELL WALLS) with CRYSTAL VIOLET dye: gram-negative or gram-positive. Eubacteria
D001424 Bacterial Infections Infections by bacteria, general or unspecified. Bacterial Disease,Bacterial Infection,Infection, Bacterial,Infections, Bacterial,Bacterial Diseases
D052899 Pore Forming Cytotoxic Proteins Proteins secreted from an organism which form membrane-spanning pores in target cells to destroy them. This is in contrast to PORINS and MEMBRANE TRANSPORT PROTEINS that function within the synthesizing organism and COMPLEMENT immune proteins. These pore forming cytotoxic proteins are a form of primitive cellular defense which are also found in human LYMPHOCYTES.

Related Publications

Minkyung Ryu, and Jaeyeong Park, and Ji-Hyun Yeom, and Minju Joo, and Kangseok Lee
January 2012, International journal of microbiology,
Minkyung Ryu, and Jaeyeong Park, and Ji-Hyun Yeom, and Minju Joo, and Kangseok Lee
November 2020, Critical reviews in biotechnology,
Minkyung Ryu, and Jaeyeong Park, and Ji-Hyun Yeom, and Minju Joo, and Kangseok Lee
December 2021, Biomolecules,
Minkyung Ryu, and Jaeyeong Park, and Ji-Hyun Yeom, and Minju Joo, and Kangseok Lee
January 2016, Frontiers in cellular and infection microbiology,
Minkyung Ryu, and Jaeyeong Park, and Ji-Hyun Yeom, and Minju Joo, and Kangseok Lee
July 2016, Journal of peptide science : an official publication of the European Peptide Society,
Minkyung Ryu, and Jaeyeong Park, and Ji-Hyun Yeom, and Minju Joo, and Kangseok Lee
January 2020, Frontiers in cellular and infection microbiology,
Minkyung Ryu, and Jaeyeong Park, and Ji-Hyun Yeom, and Minju Joo, and Kangseok Lee
June 2021, Immunotherapy,
Minkyung Ryu, and Jaeyeong Park, and Ji-Hyun Yeom, and Minju Joo, and Kangseok Lee
January 1994, Ciba Foundation symposium,
Minkyung Ryu, and Jaeyeong Park, and Ji-Hyun Yeom, and Minju Joo, and Kangseok Lee
January 2018, Microbial pathogenesis,
Minkyung Ryu, and Jaeyeong Park, and Ji-Hyun Yeom, and Minju Joo, and Kangseok Lee
January 2015, BioMed research international,
Copied contents to your clipboard!